## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

No clear thesis: MRS_10 at 3.1%, does not meet entry criteria. Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($787.55)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. 2,026 Shares in McKesson Corporation $MCK Acquired by Caldwell Trust Co**
- Source: MarketBeat | 20251216T101817 | Bullish | Relevance: 100%
- Caldwell Trust Co acquired a new stake of 2,026 shares in McKesson Corporation (NYSE:MCK) during the second quarter, valued at approximately $1,485,000. Other institutional investors also adjusted their holdings in McKesson, with Vanguard Group Inc. boosting its position by 2.0% and Norges Bank acquiring a new stake worth about $1.35 billion. Analysts currently give McKesson a "Moderate Buy" consensus rating with an average target price of $892.86.

**2. Westwood Holdings Group Inc. Boosts Stock Position in McKesson Corporation $MCK**
- Source: MarketBeat | 20251215T140627 | Somewhat-Bullish | Relevance: 100%
- Westwood Holdings Group Inc. significantly increased its stake in McKesson Corporation (NYSE:MCK) by 778.7% in the second quarter, now owning 53,690 shares valued at $39.34 million. Other institutional investors also adjusted their positions, and McKesson recently announced a quarterly dividend of $0.82 per share. Analyst ratings for MCK are generally positive, with a "Moderate Buy" consensus and an average price target of $892.86.

**3. Medication Management Market Is Going to Boom |• McKesson Corporation • Cardinal Health**
- Source: openPR.com | 20251215T110038 | Bullish | Relevance: 100%
- Worldwide Market Reports (WMR) projects substantial growth for the Medication Management Market, offering a comprehensive analysis that includes market dynamics, growth drivers, restraints, challenges, opportunities, and competitive landscapes. The report covers key market players like McKesson Corporation and Cardinal Health, along with segmental highlights by types and applications, and provides regional outlooks. It utilizes extensive primary and secondary research to deliver actionable intelligence and growth forecasts for the market from 2025 to 2032.

**4. McKesson Corporation $MCK Shares Sold by National Bank of Canada FI**
- Source: MarketBeat | 20251215T102438 | Bullish | Relevance: 100%
- National Bank of Canada FI significantly reduced its stake in McKesson Corporation, selling 40.6% of its shares. Despite this, analysts maintain a "Moderate Buy" rating with a consensus price target of $892.86. McKesson recently surpassed EPS expectations, announced a quarterly dividend of $0.82, and continues to attract institutional investment.

**5. Advisory Services Network LLC Grows Holdings in McKesson Corporation $MCK**
- Source: MarketBeat | 20251215T081317 | Bullish | Relevance: 100%
- Advisory Services Network LLC increased its stake in McKesson Corporation by 11.9% in Q2, bringing its total to 15,052 shares valued at $10.44 million. Other institutions also significantly boosted their holdings, with Norges Bank acquiring a new $1.35 billion stake. Analysts maintain a "Moderate Buy" rating for MCK, with an average price target of $892.86.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $960 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +8.8% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.98 indicates undervaluation relative to growth. Balance sheet: $2.3B free cash flow. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $102.4B |
| Beta | 0.38 |
| 52W Range | $558.13 - $895.58 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.98 |
| Forward P/E | 18.8 |
| Current P/E | 21.3 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -5.7% to 3.1% (+8.8% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 63rd percentile. MRS_5 at 2.9% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.13x) but short-term weakness (below SMA20). MACD histogram bearish (-5.06), momentum weakening. RSI neutral at 49. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.15% (CS: 64) | Strong |
| RSI_14 | 48.7 | Neutral |
| MACD Histogram | -5.06 | Bearish |
| vs SMA20 | 0.981x | Below |
| vs SMA50 | 1.005x | Above |
| vs SMA200 | 1.129x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $823.01
- **Stop Loss:** $787.55 (4.3% risk)
- **Target:** $858.47 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 33
- **Position Value:** $27,159.33
- **Portfolio %:** 27.16%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*